SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.2329

Change

+0.01 (+5.86)%

Market Cap

N/A

Volume

1.09K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.76 (+0.98%)

USD 242.22B
AMGN Amgen Inc

-1.89 (-0.59%)

USD 173.38B
SNY Sanofi ADR

-0.32 (-0.56%)

USD 144.83B
GILD Gilead Sciences Inc

+0.10 (+0.12%)

USD 104.09B
BIIB Biogen Inc

-3.04 (-1.57%)

USD 28.36B
GRFS Grifols SA ADR

-0.05 (-0.56%)

USD 7.13B
AMRN Amarin Corporation PLC

-0.01 (-1.10%)

USD 0.26B
MIRA MIRA Pharmaceuticals, Inc. Com..

-0.11 (-8.46%)

USD 0.02B
SCLX Scilex Holding Company

-0.04 (-3.85%)

N/A

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -35.31% 20% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.31% 20% F 24% F
Trailing 12 Months  
Capital Gain -59.67% 20% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.67% 20% F 14% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -21.15% N/A N/A 16% F
Dividend Return -21.15% N/A N/A 16% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 46.87% N/A N/A 38% F
Risk Adjusted Return -45.14% N/A N/A 19% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector